{"protocolSection":{"identificationModule":{"nctId":"NCT00887783","orgStudyIdInfo":{"id":"09.01"},"organization":{"fullName":"Odense University Hospital","class":"OTHER"},"briefTitle":"Navelbine And Radiotherapy in Locally Advanced Lung Cancer","officialTitle":"Induction Chemotherapy With Carboplatin and Navelbine Oral(R) Followed by Concomitant Navelbine Oral(R) and Irradiation in Local-regionally Advanced Non-small Cell Lung Cancer. A Randomized Phase II Study.","acronym":"NARLAL"},"statusModule":{"statusVerifiedDate":"2022-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-05-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2016-09-01","type":"ACTUAL"},"completionDateStruct":{"date":"2016-09-01","type":"ACTUAL"},"studyFirstSubmitDate":"2009-04-23","studyFirstSubmitQcDate":"2009-04-23","studyFirstPostDateStruct":{"date":"2009-04-24","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-07-21","resultsFirstSubmitQcDate":"2021-01-05","resultsFirstPostDateStruct":{"date":"2021-01-08","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-04-22","lastUpdatePostDateStruct":{"date":"2022-05-17","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Olfred Hansen","investigatorTitle":"MD, Professor","investigatorAffiliation":"Odense University Hospital"},"leadSponsor":{"name":"Odense University Hospital","class":"OTHER"},"collaborators":[{"name":"Aarhus University Hospital","class":"OTHER"},{"name":"Vejle Hospital","class":"OTHER"},{"name":"Rigshospitalet, Denmark","class":"OTHER"},{"name":"Aalborg University Hospital","class":"OTHER"},{"name":"Copenhagen University Hospital at Herlev","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This study is an open label randomized multi-centre phase II trial in patients with inoperable locally advanced stage IIB-IIIB Non Small Cell Lung Cancer who fulfils the general criteria for curatively intended irradiation. The treatment plan consists of two courses of inductions chemotherapy followed of concomitant therapy chemo-radiotherapy 3 weeks after day 1 of the last induction chemotherapy has been given. The patients will be included in the study after completing the induction chemotherapy. Randomization will take place only if an acceptable dose plan can be obtained.","detailedDescription":"This study was an open label randomized multi-centre phase II trial in patients with inoperable locally advanced stage IIB-IIIB Non Small Cell Lung Cancer who fulfils the general criteria for curatively intended irradiation. The treatment plan consisted of two courses of inductions chemotherapy followed of concomitant therapy chemo-radiotherapy 3 weeks after day 1 of the last induction chemotherapy has been given. The patients was included in the study after completing the induction chemotherapy. Randomization took place only if an acceptable dose plan could be obtained.\n\nPrimary endpoint: local recurrence free interval"},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"],"keywords":["Induction chemotherapy","Non-small cell lung cancer","Randomized phase II study","Navelbine Oral (R)","3D-conformal radiotherapy","Chemo-radiotherapy","Local-regionally advanced non-small cell lung cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE","maskingDescription":"No blinding after randomization"}},"enrollmentInfo":{"count":117,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"B: 66Gy/33F+Navelbine oral 150 mg q3w","type":"EXPERIMENTAL","description":"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).\n\nRadiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization","interventionNames":["Drug: Navelbine","Radiation: 66 Gy/33F"]},{"label":"A: 60Gy/30F+Navelbine oral 150 mg q3w","type":"ACTIVE_COMPARATOR","description":"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization","interventionNames":["Drug: Navelbine","Radiation: 60 Gy/30F"]}],"interventions":[{"type":"DRUG","name":"Navelbine","description":"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks","armGroupLabels":["A: 60Gy/30F+Navelbine oral 150 mg q3w","B: 66Gy/33F+Navelbine oral 150 mg q3w"],"otherNames":["Vinorelbine"]},{"type":"RADIATION","name":"66 Gy/33F","description":"irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)","armGroupLabels":["B: 66Gy/33F+Navelbine oral 150 mg q3w"]},{"type":"RADIATION","name":"60 Gy/30F","description":"irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)","armGroupLabels":["A: 60Gy/30F+Navelbine oral 150 mg q3w"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Local Failure Free Survival","description":"Local failure free survival 9 month after first RT treatment measured by CT/FDG-CT","timeFrame":"9 months"}],"secondaryOutcomes":[{"measure":"Number of Participants Who Experienced Early Toxicity to Concurrent Vinorelbine and Radiotherapy","timeFrame":"9 months"},{"measure":"Local Tumour Control","description":"Loco-regional control","timeFrame":"9 months"},{"measure":"Overall Survival","description":"Overall survival, death of any cause","timeFrame":"72 months"},{"measure":"Late Toxicity","description":"Late toxicity related to concurrent Vinorelbine and radiotherapy","timeFrame":"48 months"},{"measure":"Disease Free Survival","description":"Disease free survival, death of any cause","timeFrame":"72 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥18 years\n* Patients with histologically or cytologically documented diagnosis of locally advanced NSCLC stage IIB to IIIB without pleural effusion\n* Performance status 0-1 on the ECOG scale\n* Weight loss ≤10% during the last 6 months\n* Adequate lung function measured as FEV1 ≥1.0\n* Neutrophile count ≥1.5 x 109/L and platelet count ≥100 x 109/L\n* Serum bilirubin ≤1.5 upper limit of normal (ULN)\n* ALAT ≤2 x ULN\n* Able to comply with study and follow-up procedures\n* Patients with reproductive potential must use effective contraception\n* Written (signed) informed consent to participate in the study\n\nExclusion Criteria:\n\n* Any unstable systemic disease (including active infection, unstable angina, congestive heart failure, severe hepatic, renal, or metabolic disease)\n* Any other active malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer)\n* Prior chemotherapy for lung cancer, including neo- and adjuvant chemotherapy\n* Inability to take oral medication, or requirement of intravenous alimentation\n* Active peptic ulcer disease\n* Nursing mothers","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Olfred Hansen, MD","affiliation":"Odense University Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Department of Oncology, Aalborg University Hospital","city":"Aalborg","zip":"9100","country":"Denmark","geoPoint":{"lat":57.048,"lon":9.9187}},{"facility":"Department of Oncology, Aarhus University Hospital","city":"Aarhus","zip":"8000","country":"Denmark","geoPoint":{"lat":56.15674,"lon":10.21076}},{"facility":"Department of Oncology, Copenhagen University Hospital Herlev","city":"Herlev","zip":"2730","country":"Denmark","geoPoint":{"lat":55.72366,"lon":12.43998}},{"facility":"Department of Oncology, Odense University Hospital","city":"Odense","zip":"5000","country":"Denmark","geoPoint":{"lat":55.39594,"lon":10.38831}},{"facility":"Laboratory of Radiation Physics","city":"Odense","zip":"5000","country":"Denmark","geoPoint":{"lat":55.39594,"lon":10.38831}},{"facility":"Department of Oncology, Vejle Hospital","city":"Vejle","zip":"7100","country":"Denmark","geoPoint":{"lat":55.70927,"lon":9.5357}}]},"referencesModule":{"references":[{"pmid":"28410809","type":"RESULT","citation":"Hansen O, Knap MM, Khalil A, Nyhus CH, McCulloch T, Holm B, Brink C, Hoffmann L, Schytte T. A randomized phase II trial of concurrent chemoradiation with two doses of radiotherapy, 60Gy and 66Gy, concomitant with a fixed dose of oral vinorelbine in locally advanced NSCLC. Radiother Oncol. 2017 May;123(2):276-281. doi: 10.1016/j.radonc.2017.03.017. Epub 2017 Apr 11."}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED","description":"Further studies on toxicity profiles and PET may be performed"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"117 included July 2009 to August 2013","groups":[{"id":"FG000","title":"B: 66Gy/33F+Navelbine Oral 150 mg q3w","description":"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).\n\nRadiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization\n\nNavelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks\n\n66 Gy/33F: irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)"},{"id":"FG001","title":"A: 60Gy/30F+Navelbine Oral 150 mg q3w","description":"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization\n\nNavelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks\n\n60 Gy/30F: irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"59"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"59"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"B: 66Gy/33F+Navelbine Oral 150 mg q3w","description":"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).\n\nRadiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization\n\nNavelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks\n\n66 Gy/33F: irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)"},{"id":"BG001","title":"A: 60Gy/30F+Navelbine Oral 150 mg q3w","description":"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization\n\nNavelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks\n\n60 Gy/30F: irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"117"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"117"}]}],"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"54"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"63"}]}]}]},{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"117"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"64.56","lowerLimit":"44.38","upperLimit":"79.39"},{"groupId":"BG001","value":"66.63","lowerLimit":"44.68","upperLimit":"81.98"},{"groupId":"BG002","value":"65.53","lowerLimit":"44.38","upperLimit":"81.98"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"117"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"62"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"55"}]}]}]},{"title":"Race and Ethnicity Not Collected","populationDescription":"Race and Ethnicity were not collected from any participant.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Denmark","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"117"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"117"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Local Failure Free Survival","description":"Local failure free survival 9 month after first RT treatment measured by CT/FDG-CT","populationDescription":"Analyzed as intention to treat","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"months","timeFrame":"9 months","groups":[{"id":"OG000","title":"B: 66Gy/33F+Navelbine Oral 150 mg q3w","description":"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).\n\nRadiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization\n\nNavelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks\n\n66 Gy/33F: irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)"},{"id":"OG001","title":"A: 60Gy/30F+Navelbine Oral 150 mg q3w","description":"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization\n\nNavelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks\n\n60 Gy/30F: irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"59"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","lowerLimit":"2.8","upperLimit":"67"},{"groupId":"OG001","value":"9.9","lowerLimit":"2.6","upperLimit":"54"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Experienced Early Toxicity to Concurrent Vinorelbine and Radiotherapy","populationDescription":"Dysphagia, weight loss ≥20%, pulmonary toxicity grade 3, leucopenia grade 3 or higher","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"9 months","groups":[{"id":"OG000","title":"B: 66Gy/33F+Navelbine Oral 150 mg q3w","description":"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).\n\nRadiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization\n\nNavelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks\n\n66 Gy/33F: irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)"},{"id":"OG001","title":"A: 60Gy/30F+Navelbine Oral 150 mg q3w","description":"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization\n\nNavelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks\n\n60 Gy/30F: irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"59"}]}],"classes":[{"title":"Dysphagia g3+","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"}]}]},{"title":"Pulmonary tox","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"11"}]}]},{"title":"Leucopenia g3+","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}]}]}]},{"type":"SECONDARY","title":"Local Tumour Control","description":"Loco-regional control","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2022-09","timeFrame":"9 months","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival, death of any cause","populationDescription":"Overall survival, intention to treat","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Months","timeFrame":"72 months","groups":[{"id":"OG000","title":"B: 66Gy/33F+Navelbine Oral 150 mg q3w","description":"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).\n\nRadiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization\n\nNavelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks\n\n66 Gy/33F: irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)"},{"id":"OG001","title":"A: 60Gy/30F+Navelbine Oral 150 mg q3w","description":"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization\n\nNavelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks\n\n60 Gy/30F: irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"59"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.3","lowerLimit":"3.0","upperLimit":"68"},{"groupId":"OG001","value":"23.3","lowerLimit":"3.2","upperLimit":"65.6"}]}]}]},{"type":"SECONDARY","title":"Late Toxicity","description":"Late toxicity related to concurrent Vinorelbine and radiotherapy","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2022-09","timeFrame":"48 months","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Disease Free Survival","description":"Disease free survival, death of any cause","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Months","timeFrame":"72 months","groups":[{"id":"OG000","title":"B: 66Gy/33F+Navelbine Oral 150 mg q3w","description":"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).\n\nRadiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization\n\nNavelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks\n\n66 Gy/33F: irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)"},{"id":"OG001","title":"A: 60Gy/30F+Navelbine Oral 150 mg q3w","description":"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization\n\nNavelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks\n\n60 Gy/30F: irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"59"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","lowerLimit":".2","upperLimit":"68"},{"groupId":"OG001","value":"8.8","lowerLimit":".2","upperLimit":"54"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"5 years, death or recurrence","eventGroups":[{"id":"EG000","title":"B: 66Gy/33F+Navelbine Oral 150 mg q3w","description":"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).\n\nRadiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization\n\nNavelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks\n\n66 Gy/33F: irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)","deathsNumAffected":41,"deathsNumAtRisk":58,"seriousNumAffected":18,"seriousNumAtRisk":58,"otherNumAffected":25,"otherNumAtRisk":58},{"id":"EG001","title":"A: 60Gy/30F+Navelbine Oral 150 mg q3w","description":"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization\n\nNavelbine: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks\n\n60 Gy/30F: irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)","deathsNumAffected":44,"deathsNumAtRisk":59,"seriousNumAffected":15,"seriousNumAtRisk":59,"otherNumAffected":20,"otherNumAtRisk":59}],"seriousEvents":[{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Pneumonitis, pneumonia, embolus","stats":[{"groupId":"EG000","numEvents":17,"numAffected":15,"numAtRisk":58},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":59}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Dysphagia, esophagitis, stenosis, obstipation, nausea","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":58},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":59}]},{"term":"Herpes zoster","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Herpes zoster","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":59}]},{"term":"Atrial fibrilation","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Atrial flutter","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":58},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":59}]}],"otherEvents":[{"term":"Leucopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":58},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":59}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":58},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":59}]},{"term":"Pulmonary toxicity","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":58},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":59}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Dr. Olfred Hansen, Professor, Ph.D.","organization":"Dept. Oncology, Odense University Hospital","email":"olfred.hansen@rsyd.dk","phone":"+4524241588"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077235","term":"Vinorelbine"}],"ancestors":[{"id":"D014748","term":"Vinca Alkaloids"},{"id":"D046948","term":"Secologanin Tryptamine Alkaloids"},{"id":"D026121","term":"Indole Alkaloids"},{"id":"D000470","term":"Alkaloids"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D007211","term":"Indoles"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D054836","term":"Indolizidines"},{"id":"D007212","term":"Indolizines"}]}},"hasResults":true}